Literature DB >> 20506008

Heart rate response during vasodilator stress myocardial perfusion imaging: Mechanisms and implications.

Fadi G Hage, Ami E Iskandrian.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20506008     DOI： 10.1007/s12350-010-9248-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  22 in total

1.  Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms.

Authors:  Rohit Bhatheja; Gary S Francis; Claire E Pothier; Michael S Lauer
Journal:  Am J Cardiol       Date:  2005-05-15       Impact factor: 2.778

2.  Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists.

Authors:  C Alberti; A Monopoli; C Casati; A Forlani; C Sala; B Nador; E Ongini; A Morganti
Journal:  J Cardiovasc Pharmacol       Date:  1997-09       Impact factor: 3.105

3.  Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging.

Authors:  Shishir Mathur; Anuj R Shah; Alan W Ahlberg; Deborah M Katten; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2010-05-19       Impact factor: 5.952

4.  Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study.

Authors:  Aiden Abidov; Rory Hachamovitch; Sean W Hayes; Chee Keong Ng; Ishac Cohen; John D Friedman; Guido Germano; Daniel S Berman
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

5.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

Review 6.  The scope of coronary heart disease in patients with chronic kidney disease.

Authors:  Fadi G Hage; Rajesh Venkataraman; Gilbert J Zoghbi; Gilbert J Perry; Angelo M DeMattos; Ami E Iskandrian
Journal:  J Am Coll Cardiol       Date:  2009-06-09       Impact factor: 24.094

7.  Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients.

Authors:  D L Johnston; J R Daley; D O Hodge; M R Hopfenspirger; R J Gibbons
Journal:  Mayo Clin Proc       Date:  1995-04       Impact factor: 7.616

8.  Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction.

Authors:  Tetsuo Sasano; M Roselle Abraham; Kuan-Cheng Chang; Hiroshi Ashikaga; Kevin J Mills; Daniel P Holt; John Hilton; Stephan G Nekolla; Jun Dong; Albert C Lardo; Henry Halperin; Robert F Dannals; Eduardo Marbán; Frank M Bengel
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

9.  Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death.

Authors:  Jonathan P Piccini; John R Horton; Linda K Shaw; Sana M Al-Khatib; Kerry L Lee; Ami E Iskandrian; Salvador Borges-Neto
Journal:  Circ Cardiovasc Imaging       Date:  2008-09-17       Impact factor: 7.792

10.  Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.

Authors:  Fadi G Hage; Jaekyeong Heo; Billy Franks; Luiz Belardinelli; Brent Blackburn; Whedy Wang; Ami E Iskandrian
Journal:  Am Heart J       Date:  2009-03-06       Impact factor: 4.749
View more
  7 in total

Review 1.  Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be?

Authors:  Leslee J Shaw; Fadi G Hage; Daniel S Berman; Rory Hachamovitch; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

2.  Heart rate response to regadenoson: Making the case for its value in clinical practice.

Authors:  Efstathia Andrikopoulou; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2015-08-27       Impact factor: 5.952

3.  Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECT-related variables.

Authors:  Athanasios Katsikis; Athanasios Theodorakos; Spyridon Papaioannou; Antonios Kalkinis; Genovefa Kolovou; Konstantinos Konstantinou; Maria Koutelou
Journal:  J Nucl Cardiol       Date:  2017-04-26       Impact factor: 5.952

4.  Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.

Authors:  Gurunanthan Palani; Zehra Husain; Rafael Cabrera Salinas; Vanji Karthikeyan; Aarthee S Karthikeyan; Karthik Ananthasubramaniam
Journal:  J Nucl Cardiol       Date:  2011-05-04       Impact factor: 5.952

5.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

6.  Safety and tolerability of regadenoson CMR.

Authors:  Kim-Lien Nguyen; W Patricia Bandettini; Sujata Shanbhag; Steve W Leung; Joel R Wilson; Andrew E Arai
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-01-21       Impact factor: 6.875

7.  Reduced Sympathetic Reserve Detectable by Heart Rate Response after Dipyridamole in Anginal Patients with Normal Coronary Arteries.

Authors:  Lauro Cortigiani; Clara Carpeggiani; Laura Meola; Ana Djordjevic-Dikic; Francesco Bovenzi; Eugenio Picano
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.